PharmaTher Secures Key US Patent for Ketamine in Amyotrophic Lateral Sclerosis (ALS), Bolstering its Orphan Drug Designated Program and Targeting a Billion Dollar Market

TORONTO, June 24, 2025 -- PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) ("PharmaTher" or the "Company"), a company focused on unlocking the pharmaceutical potential of ketamine, is pleased to announce that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,128,012, expiring May 14, 2041, for the use of ketamine in the treatment of Amyotrophic Lateral Sclerosis (ALS).

This newly issued patent significantly strengthens the Company’s intellectual property portfolio and provides robust protection for its clinical development program for ketamine in ALS. This achievement complements PharmaTher's existing Orphan Drug Designation (ODD) for ketamine, granted by the U.S. Food and Drug Administration (FDA), creating a powerful strategic advantage in addressing this devastating neurodegenerative disease.

“The grant of this U.S. patent is a monumental achievement for PharmaTher and a critical step in solidifying our leadership position in developing novel ketamine therapies for severe neurological disorders,” said Fabio Chianelli, CEO of PharmaTher. “Combined with our Orphan Drug Designation, we have built a formidable moat around our ketamine program for ALS. This dual protection of intellectual property and regulatory exclusivity is a cornerstone of our strategy to unlock significant shareholder value as we advance towards clinical development and potential commercialization for a patient population with an urgent unmet medical need.”

The Unmet Need in ALS: A Devastating Disease
Amyotrophic Lateral Sclerosis, often known as Lou Gehrig's disease, is a progressive and fatal neurodegenerative disorder that affects nerve cells in the brain and spinal cord. ALS leads to the gradual loss of muscle control, impacting the ability to speak, eat, move, and eventually breathe. Currently, there is no cure for ALS, and existing treatments offer only modest benefits in slowing disease progression, highlighting a desperate need for new and more effective therapeutic options.

Market Opportunity and Strategic Advantage
The market for ALS treatments represents a significant commercial opportunity, driven by a high unmet need and a dedicated patient advocacy community.

• Incidence & Population: Approximately 5,000 new cases of ALS are diagnosed each year in the U.S., with an estimated 30,000 people currently living with the disease in the United States alone.
• Market Size: The global ALS treatment market is projected to reach over USD $1.04 billion by 2030, according to projections from Precedence Research, with the potential to grow substantially with the introduction of novel, disease-modifying therapies.

PharmaTher’s strategy is uniquely positioned to capture this market. The combination of the new patent and the FDA Orphan Drug Designation creates a powerful value proposition:

1. Patent Protection: The newly granted patent provides long-term (patent expiry May 14, 2041), defensible intellectual property rights for the Company’s specific method of using ketamine to treat ALS.
2. FDA Orphan Drug Designation (ODD): The ODD provides powerful incentives, including:

• Seven years of market exclusivity in the U.S. following drug approval.
• Tax credits for qualified clinical trials.
• Exemption from FDA application fees of approximately $2.4 million.
• Regulatory guidance and assistance from the FDA.

3. FDA Fast Track Designation and Clinical Study: The FDA had accepted an investigator-initiated IND to proceed with a Phase 2 clinical study evaluating ketamine for ALS. The study’s primary investigator is Dr. Richard Barohn, M.D. Upon completion of the study, the Company will seek FDA Fast Track designation and meeting for a proposed Phase 3 study in 2026.

Mr. Chianelli added, “Our robust strategy is designed to de-risk the development pathway and maximize the commercial potential of ketamine for ALS. We are now in a strong position to advance our clinical program, pursue strategic partnerships, and ultimately deliver a potentially life-altering therapy to patients.”

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is focused on the research and commercialization of KETARX™ (Ketamine) to fill the unmet medical needs for surgery, pain, mental health, neurological, and medical countermeasures indications. Learn more at PharmaTher.com.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “closer”, "could", “confident”, "would", "intend", "expect", "believe", "will", "projected", "estimated", "potential", "aim", “may”, “plan”, “proposed”, “lead”, “toward”, “anticipate”, “provide”, and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the "Company") current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption "Risk Factors" in Company's management's discussion and analysis for the three and nine months ended February 28, 2025 dated April 24, 2025, which is available on the Company's profile at www.sedarplus.ca.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.